Braveheart Bio, Inc. (BRVE)

Braveheart Bio Financials Overview

Financials in millions USD. Fiscal year is January - December.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025
Period Ending	Mar 31, 2026	Dec 31, 2025
Operating Income Operating Income Growth	-19.46	-4.51
Net Income Net Income Growth	-80.23	-66.05
Earnings Per Share EPS Growth	-2.63	-3.93
EPS Growth	-	-

Cash & Debt

Chart

Fiscal Year	Current	FY 2025
Period Ending	Mar 31, 2026	Dec 31, 2025
Net Cash (Debt) Net Cash Growth	79.91	89.16
Net Cash Growth	-	-
Net Cash Per Share Net Cash Per Share Growth	2.62	5.30
Cash & Investments Cash & Investments Growth	79.91	89.16

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025
Period Ending	Mar 31, 2026	Dec 31, 2025
Operating Cash Flow Operating Cash Flow Growth	-7.2	-2.01
Free Cash Flow Free Cash Flow Growth	-7.2	-2.01
Free Cash Flow Growth	-	-

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 31, 2026

Data Sources Report a data error